Posted on October 14, 2019 by staff

Listed AI HealthTech firm appoints expert to board


Listed HealthTech firm Renalytix AI has announced the appointment of leading kidney investigator and clinician Dr. Chirag Parikh to its board.

The firm, a developer of AI-enabled clinical diagnostics for kidney disease, is part of healthcare group EKF Diagnostics and floated in 2018.

Dr. Parikh, the director of the Division of Nephrology and the Ronald Peterson Professor of Medicine at the Johns Hopkins School of Medicine, received his medical degree from Seth G.S. Medical College and KEM Hospital in Mumbai, India and subsequently completed his internal medicine residency at the Nassau University Medical Center and SUNY at Stony Brook in New York, followed by his fellowship in Nephrology and Hypertension and UNOS Transplant Certification at the University of Colorado.

While completing his fellowship, he also earned a doctorate in Clinical Investigation.

Before joining Johns Hopkins, he was faculty at the Yale School of Medicine for over a decade and also directed the Program of Applied Translational Research.

He was also promoted to Professor of Medicine and Investigative Medicine at Yale, and Professor of Medicine at the Clinical Epidemiology Research Center in the VA Connecticut Health Care System.

His research has focused on the translation and validation of novel biomarkers for the diagnosis and prognosis of acute kidney injury.

He has been the recipient of numerous honors, including the 2017 Young Investigator Award from the American Society of Nephrology, in recognition of his ability to translate findings in the laboratory to the advancement of clinical outcomes.

James McCullough, CEO of RenalytixAI, said: “We are honoured to have one of the leading voices in kidney disease clinical practice and research join our board. Chirag will help ensure we maintain the highest standards of data driven development for the KidneyIntelX programme.”

The firm is led by non-exec chairman Julian Baines, CEO James McCullough and CTO Fergus Fleming.